Study #2022-0096
GS-US-570-6015; A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination with an Anti-PD-1 Monoclonal Antibody in Adults with Advanced Solid
MD Anderson Study Status
Enrolling
Treatment Agent
Denikitug, Zimberelimab
Description
This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced solid tumors who have received, been intolerant to, or been ineligible for all treatments known to confer clinical benefit or in participants with select solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Jaffer Ajani
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-327-0346
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.